Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,102
Completed, industry sponsors, Immunology and inflammation, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,102
1,102 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
NCT06011733 · 133 participants · Start Oct 31, 2023 · Primary completion Feb 5, 2025
Drug: Bimekizumab · For: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis
Sites: Beijing, China; Guangzhou, China; Hangzhou, China · 18 sites in all
- A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)Pivotal-lookingCompleted
Lynk Pharmaceuticals Co., LtdIndustry
NCT06276998 · 430 participants · Start Dec 12, 2023 · Primary completion Aug 22, 2025
Drug: LNK01001; Placebo · For: Rheumatoid Arthritis
Sites: Beijing, China
- Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic DermatitisPivotal-lookingCompleted
Polisorb Joint Stock CompanyIndustry
NCT07929181 · 161 participants · Start Apr 10, 2024 · Primary completion Nov 28, 2024
Drug: Colloidal Silicon Dioxide; Basic Therapy for Atopic Dermatitis · For: Atopic Dermatitis
Sites: Chelyabinsk, Russia; Krasnodar, Russia; Ryazan, Russia · 7 sites in all
- To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06552520 · 500 participants · Start Oct 8, 2024 · Primary completion Sep 11, 2025
Drug: TQH2722 injection; Placebo of TQH2722 injection · For: Atopic Dermatitis
Sites: Bengbu, China; Tongling, China; Wuhu, China · 73 sites in all
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsPivotal-lookingCompleted
Organon and CoIndustry
NCT05172726 · 58 participants · Start Dec 2, 2021 · Primary completion Oct 14, 2026
Drug: tapinarof cream, 1% · For: Plaque Psoriasis
Sites: Rogers, Arkansas; Fountain Valley, California; Rancho Santa Margarita, California · 19 sites in all
Sun Pharmaceutical Industries LimitedIndustry
NCT01729754 · 1,090 participants · Start Feb 5, 2013 · Primary completion Sep 28, 2015
Drug: Tildrakizumab 200 mg; Tildrakizumab 100 mg and 3 more · For: Plaque Psoriasis
- A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT06323356 · 18 participants · Start Mar 19, 2024 · Primary completion Oct 17, 2025
Drug: TAK-279 · For: Generalized Pustular Psoriasis; Erythrodermic Psoriasis
Sites: Nagoya, Japan; Toyoake, Japan; Kisarazu, Japan · 20 sites in all
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT05526222 · 443 participants · Start Jul 14, 2022 · Primary completion Aug 5, 2025
Drug: Jaktinib Hydrochloride Tablet · For: Atopic Dermatitis
Sites: Beijing, China; Nanjing, China
- Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha AgentPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04936308 · 453 participants · Start Sep 28, 2021 · Primary completion Oct 28, 2024
Drug: Guselkumab; Placebo · For: Arthritis, Psoriatic
Sites: Mountain Brook, Alabama; Avondale, Arizona; Flagstaff, Arizona · 169 sites in all
- Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02612454 · 880 participants · Start Oct 15, 2015 · Primary completion Oct 9, 2026
Drug: Dupilumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Gilbert, Arizona; Bakersfield, California · 84 sites in all
- A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT05676242 · 207 participants · Start Jan 11, 2023 · Primary completion Mar 12, 2026
Drug: Jaktinib Hydrochloride Tablet · For: Atopic Dermatitis
Sites: Beijing, China; Nanjin, China
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Alumis IncIndustry
NCT06586112 · 912 participants · Start Jul 25, 2024 · Primary completion Sep 19, 2025
Drug: Envudeucitinib; Apremilast and 1 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Rogers, Arkansas · 156 sites in all
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001Pivotal-lookingCompleted
Alumis IncIndustry
NCT06588738 · 862 participants · Start Aug 20, 2024 · Primary completion Sep 23, 2025
Drug: Envudeucitinib; Placebo and 1 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 124 sites in all
- A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06088199 · 51 participants · Start Oct 24, 2023 · Primary completion Aug 12, 2026
Drug: Apremilast · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Fort Smith, Arkansas · 30 sites in all
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic TherapyPivotal-lookingCompleted
LEO PharmaIndustry
NCT05958407 · 235 participants · Start Aug 28, 2023 · Primary completion May 5, 2025
Drug: Tralokinumab; Placebo · For: Atopic Dermatitis; Atopic Hand Eczema
Sites: Birmingham, Alabama; Fort Smith, Arkansas; Fountain Valley, California · 69 sites in all
- Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Huabo Biopharm Co., Ltd.Industry
NCT06477237 · 408 participants · Start Mar 29, 2024 · Primary completion Nov 15, 2024
Drug: HB0017 Q4W; HB0017 Q8W and 1 more · For: Psoriasis
Sites: Jiangmen, China; Nanyang, China; Beijing, China · 44 sites in all
- Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic DermatitisPivotal-lookingCompleted
Galderma R&DIndustry
NCT03989206 · 1,935 participants · Start Dec 30, 2019 · Primary completion Aug 31, 2026
Drug: Nemolizumab · For: Moderate-to-Severe Atopic Dermatitis
Sites: Birmingham, Alabama; Guntersville, Alabama; Scottsdale, Arizona · 343 sites in all
- Safety and Efficacy of IDP-122 in Participants With Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02515097 · 213 participants · Start Nov 5, 2015 · Primary completion Mar 15, 2017
Drug: IDP-122 Lotion; IDP-122 Vehicle Lotion · For: Plaque Psoriasis
Sites: Santa Ana, California; Boynton Beach, Florida; Clearwater, Florida · 15 sites in all
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04630028 · 112 participants · Start Mar 17, 2021 · Primary completion May 8, 2025
Drug: Ustekinumab Dose Based on BSA and Body Weight; Matching Placebo · For: Colitis, Ulcerative
Sites: Wilmington, Delaware; Atlanta, Georgia; Rochester, Minnesota · 58 sites in all
- Safety and Efficacy of IDP-118 in Participants With Plaque PsoriasisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02462122 · 215 participants · Start Aug 19, 2015 · Primary completion Nov 9, 2016
Drug: IDP-118 Lotion; IDP-118 Vehicle Lotion · For: Plaque Psoriasis
Sites: Fremont, California; Boynton Beach, Florida; North Miami Beach, Florida · 16 sites in all
- A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06280716 · 301 participants · Start Apr 24, 2024 · Primary completion Sep 25, 2025
Drug: Placebo; Lebrikizumab and 1 more · For: Atopic Dermatitis
Sites: Wuhu, China; Beijing, China; Chongqing, China · 46 sites in all
- A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT06238817 · 241 participants · Start Apr 26, 2024 · Primary completion May 21, 2025
Drug: Ruxolitinib Cream; Vehicle Cream · For: Atopic Dermatitis
Sites: Little Rock, Arkansas; Fountain Valley, California; Fremont, California · 94 sites in all
- A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid ArthritisPivotal-lookingCompleted
mAbxience Research S.L.Industry
NCT06596772 · 501 participants · Start Oct 3, 2024 · Primary completion Feb 20, 2026
Drug: MB04 (proposed biosimilar to etanercept); Enbrel (etanercept) · For: Rheumatoid Arthritis (RA)
Sites: Haskovo, Bulgaria; Plovdiv, Bulgaria; Rousse, Bulgaria · 60 sites in all
- A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingCompleted
Janssen Pharmaceutical K.K.Johnson & Johnson (Janssen) (JNJ)
NCT04397263 · 38 participants · Start Jun 10, 2020 · Primary completion Feb 29, 2024
Drug: Guselkumab · For: Crohns Disease
Sites: Abiko, Japan; Bunkyō City, Japan; Hitachi, Japan · 25 sites in all
- A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05565560 · 21 participants · Start Jan 25, 2023 · Primary completion Nov 20, 2025
Drug: Apremilast · For: Plaque Psoriasis
Sites: Nagoya, Japan; Fukuoka, Japan; Kitakyushu-shi, Japan · 29 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.